Biotech News Alert: GenSpera, Inc. (OTCQB:GNSZ) Featured in TheStockRadio.com Interview
SAN ANTONIO - December 2, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing innovative prodrug therapeutics for the treatment of cancer, releases a recent audio interview with TheStockRadio.com. Craig Dionne, PhD, GenSpera's CEO, discusses the company's background and history including the inception and development of the company's lead compound, mipsagargin, at John Hopkins University and its subsequent development by the company. Dr. Dionne also highlights the benefits of mipsagargin over traditional chemotherapeutics, including its limited side effects and more effective tumor killing properties.
Finally, Dr. Dionne provides an update as to the company's current Phase II clinical trials in liver cancer and glioblastoma (brain cancer) as well as future Phase II clinical trials in prostate cancer and kidney cancer and possibly even lung and breast cancers that have metastasized to the brain.
All information discussed has been publicly disclosed in press releases and filings.
Hear the full interview here: http://thestockradio.com/gnsz-genspera-inc-pres-ceo-craig-dionne/
Learn more about TheStockRadio.com
Read this release in full at http://www.investorideas.com/CO/GNSZ/news/2014/12021.asp
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.
The US Food and Drug Administration (FDA) granted Orphan Drug designation in 2013 for the evaluation of mipsagargin in patients with hepatocellular carcinoma. Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma (liver cancer) and glioblastoma patients (brain cancer).
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Company presentations are available at: http://www.genspera.com/
Watch the Corporate Video: http://youtu.be/jULjEul-mBk
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Craig Dionne, PhD, CEO
Craig Dionne, PhD, CEO
Capital Markets Group
Capital Markets Group
Media: Dawn Van Zant
Visit this company: www.genspera.com
More info on GNSZ at Investorideas.com Visit: http://www.investorideas.com/CO/GNSZ/
Disclaimer/Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock directories 24/7 – biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/